1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist
about
In silico molecular comparisons of C. elegans and mammalian pharmacology identify distinct targets that regulate feedingCharacterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonistOxytocin signaling in mouse taste budsOxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.REVIEW: Oxytocin: Crossing the bridge between basic science and pharmacotherapyA Gly/Ala switch contributes to high affinity binding of benzoxazinone-based non-peptide oxytocin receptor antagonists.Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells.Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonistSynthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors.Differential contributions of vasopressin V1A and oxytocin receptors in the amygdala to pain-related behaviors in rats.Modeling the human oxytocin receptor for drug discovery efforts.Small molecule ligands for oxytocin and vasopressin receptors.Identification of an extracellular segment of the oxytocin receptor providing agonist-specific binding epitopes.Design of oxytocin antagonists, which are more selective than atosiban.
P2860
Q27316596-FC2B01F2-0386-414F-A25D-93AF51F94CD6Q28379390-4F94A404-03D7-4953-9E46-08A6C25954CBQ33654270-97FFC532-E300-4C75-ADAC-C5550EE816D5Q34257617-9F1D6152-EC9E-416C-880A-B85BD7BABE99Q34275403-9F16CD86-1346-4069-BC9C-0ABCA02AC762Q34383214-1725CB6E-8C4D-4F31-9098-913586318C68Q35107577-24ABCE47-0B3D-4A6A-814B-16938B222046Q35545067-4885F1FA-F101-495A-B599-4DB152A01D85Q36983921-A1E9DB59-5CBC-4A49-857E-E6ED0289FA06Q37426019-18C23C2A-E517-43C9-9CA3-669C7D8A7F7BQ38089132-196EE938-EB89-4A3B-9E4A-747D2BFC4ECBQ41287153-CBE3C0F0-A8BD-4504-847F-4B8B492D62EAQ42005700-67F4A221-2E4A-490C-B812-AD8B93A3FEF8Q43756689-70809C55-DB62-4DE5-9F97-0E988DC5A6A3
P2860
1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist
description
1995 nî lūn-bûn
@nan
1995 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
1-(1-[4-[(N-acetyl-4-piperidin ...... on-peptide oxytocin antagonist
@ast
1-(1-[4-[(N-acetyl-4-piperidin ...... on-peptide oxytocin antagonist
@en
1-(1-[4-[(N-acetyl-4-piperidin ...... on-peptide oxytocin antagonist
@nl
type
label
1-(1-[4-[(N-acetyl-4-piperidin ...... on-peptide oxytocin antagonist
@ast
1-(1-[4-[(N-acetyl-4-piperidin ...... on-peptide oxytocin antagonist
@en
1-(1-[4-[(N-acetyl-4-piperidin ...... on-peptide oxytocin antagonist
@nl
prefLabel
1-(1-[4-[(N-acetyl-4-piperidin ...... on-peptide oxytocin antagonist
@ast
1-(1-[4-[(N-acetyl-4-piperidin ...... on-peptide oxytocin antagonist
@en
1-(1-[4-[(N-acetyl-4-piperidin ...... on-peptide oxytocin antagonist
@nl
P2093
P356
P1476
1-(1-[4-[(N-acetyl-4-piperidin ...... on-peptide oxytocin antagonist
@en
P2093
B V Clineschmidt
D J Pettibone
J M Pawluczyk
M T Guidotti
P D Williams
R M Freidinger
P304
P356
10.1021/JM00023A002
P407
P577
1995-11-10T00:00:00Z